Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

February 27, 2018   |   News

BIAL signed Exclusive Licensing Agreements for Zebinix and Ongentys in South Korea

The partnership with two South Korean companies marks BIALís entry in another Asian market

BIAL signed two Exclusive Licensing Agreements for Eslicarbazepine Acetate and Opicapone - its innovative products for Epilepsy and Parkinson’s Disease, respectively -, in South Korea.

These two agreements mark BIAL’s entry in another Asian market and raises to 60 the number of countries where BIAL already has licensed and commercialized products. 

BIAL signed an exclusive licensing agreement with WhanIn Pharm. Co., Ltd. for the importation, packaging and commercialization of Zebinix. Regarding Ongentys, a similar agreement was signed with SK Chemicals Co., Ltd.

António Portela, CEO of BIAL, explains that "Similarly to what has been announced this year for China, with these partnerships BIAL is reaching a new market, also in Asia, within its internationalization project. We are confident that we have chosen good partners with expertise in the area of central nervous system, and hopefully within a few years it will be possible to market these innovative medicines in South Korea."